Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1,2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development.

Full Abstract

Diet-induced changes in the activities of bacterial enzymes are known to play a role in colon cancer development. Resveratrol has been implicated as a protective agent in carcinogenesis. In the present study, the effect of resveratrol on the activities of faecal and colonic biotransforming enzymes such as beta-glucuronidase, beta-glucosidase, beta-galactosidase, mucinase, nitroreductase and faecal sulfatase activity was assessed. The total number of aberrant crypt foci and their distribution in the proximal, medial and distal colon were observed in 1,2-dimethylhydrazine (DMH)-induced rats (group 3) and other treatment groups (groups 4-6). DMH (0.02 g/kg body weight) was given subcutaneously once a week for 15 consecutive weeks, and the experiment was terminated at 30 weeks. DMH-treated rats showed elevated levels of cancer-associated bacterial enzyme activities, whereas on resveratrol supplementation in three different regimens, rats showed lowered activities. Resveratrol supplementation throughout the experimental period (group 6) exerted a more pronounced effect (P < 0.01) by modulating the development of aberrant crypt foci and the activities of bacterial enzymes than did the other treatment regimens (groups 4 and 5). Thus, the present results demonstrate the inhibitory effect of resveratrol on DMH-induced colon carcinogenesis in rats.

Learn Faster Today Improve your study skills

Author information

Author/s: Sengottuvelan, Murugan (M); Nalini, Namasivayam (N);

Affiliation: Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar - 608 002, Tamilnadu, India.

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal: The British journal of nutrition (Br J Nutr), published in England. (Language: eng)

Reference: 2006-Jul; vol 96 (issue 1) : pp 145-53

Dates: Created 2006/07/27; Completed 2006/08/22; Revised 2006/11/15;

PMID: 16870003, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

1,2-Dimethylhydrazine
Animals
Antineoplastic Agents, Phytogenic - administration & dosage
Bacteria - enzymology
Carcinogens
Colon - enzymology; microbiology
Colonic Neoplasms - chemically induced; enzymology; pathology; prevention & control
Dietary Supplements
Disease Models, Animal
Feces - enzymology

Glycoside Hydrolases - metabolism
Intestinal Mucosa - enzymology
Male
Nitroreductases - metabolism
Polysaccharide-Lyases - metabolism
Precancerous Conditions - pathology
Rats
Rats, Wistar
Stilbenes - administration & dosage
Sulfatases - metabolism

Associated Chemicals: Antineoplastic Agents, Phytogenic (0) ; Carcinogens (0) ; Stilbenes (0) ; resveratrol (501-36-0) ; 1,2-Dimethylhydrazine (540-73-8) ; Nitroreductases (EC 1.7.-) ; Sulfatases (EC 3.1.6.-) ; Glycoside Hydrolases (EC 3.2.1.-) ; Polysaccharide-Lyases (EC 4.2.2.-) ; hyaluronate lyase (EC 4.2.2.1)

These are the highest related articles currently in the database:

See 100+ related articles.